Followers | 4057 |
Posts | 151999 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Thursday, December 07, 2023 4:13:03 PM
Recent ALGS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:05:59 PM
- Aligos Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 08/15/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:09:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:08:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:11:01 PM
- Aligos Therapeutics Strengthens Board with Two New Independent Directors • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:14:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:05:31 PM
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 • GlobeNewswire Inc. • 07/30/2024 08:05:00 PM
- Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. • GlobeNewswire Inc. • 07/22/2024 01:00:00 PM
- Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:56 PM
- Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 • GlobeNewswire Inc. • 05/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:02:52 PM
- Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH • GlobeNewswire Inc. • 05/21/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:05:32 PM
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 08:05:00 PM
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM